Kymera Therapeutics Director Granted Stock Options Worth Potential Millions

Rhea-AI Filing Summary

Elena Ridloff, Director at Kymera Therapeutics (KYMR), received a stock option grant on June 25, 2025. The derivative securities transaction involved:

• Grant of 16,000 stock options to purchase common stock
• Exercise price set at $46.47 per share
• Options expire on June 24, 2035
• Vesting schedule: Full vesting upon the earlier of June 25, 2026 or the next annual stockholders' meeting

This Form 4 filing represents a standard director compensation equity grant. The options provide Ridloff with the right to purchase company shares at the specified strike price, aligning her interests with shareholders through direct equity ownership potential.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ridloff Elena

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	16,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 16,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ridloff Elena

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$46.47	06/25/2025		A		16,000		(1)	06/24/2035	Common Stock	16,000	$0	16,000	D

Explanation of Responses:

1. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 25, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders.

	/s/ Bruce Jacobs, as Attorney-in-Fact	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options were granted to Elena Ridloff at KYMR on June 25, 2025?

Elena Ridloff was granted 16,000 stock options with an exercise price of $46.47 per share. These options have an expiration date of June 24, 2035 and were granted as part of her role as Director at Kymera Therapeutics.

When do Elena Ridloff's KYMR stock options vest?

The stock options will vest in full upon the earlier of two dates: (i) June 25, 2026 or (ii) the date of Kymera Therapeutics' next annual stockholders meeting.

What is Elena Ridloff's role at KYMR?

According to the Form 4 filing, Elena Ridloff serves as a Director on Kymera Therapeutics' board, as indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.

What is the exercise price and expiration date of KYMR stock options granted in June 2025?

The stock options were granted with an exercise price of $46.47 per share and have an expiration date of June 24, 2035, ten years from the grant date.

How many KYMR derivative securities does Elena Ridloff own after this transaction?

Following this transaction, Elena Ridloff beneficially owns 16,000 derivative securities (stock options) of Kymera Therapeutics in direct ownership form.